Sky Century Investment (SKYI) Current Deferred Revenue (2025 - 2026)
Sky Century Investment (SKYI) posted quarterly Current Deferred Revenue of $26584.0 for Q2 2026, up 1816.65% year-over-year from $1387.0 in Q2 2025, and up 92.62% quarter-over-quarter from $13801.0 in Q1 2026.
Sky Century Investment (SKYI) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has reported Current Deferred Revenue for 2 consecutive years, with $26584.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Deferred Revenue rose 1816.65% year-over-year to $26584.0; the TTM figure through May 2026 stood at $26584.0 (up 1816.65% YoY), while the FY2025 annual figure was $27550.0, changed N/A from the prior year.
- Current Deferred Revenue advanced to $26584.0 in Q2 2026 per SKYI's latest filing, from $13801.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $27550.0 in Q3 2025 and bottomed at $1387.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Sky Century Investment | 393,547.71 | 393,283.71 | 26,045.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 26,584.00 |
| Feb 28, 2026 | 13,801.00 |
| Nov 30, 2025 | 23,998.00 |
| Aug 31, 2025 | 27,550.00 |
| May 31, 2025 | 1,387.00 |